IL33 and Myocardial fibrosis: ST2L and sST2 bind to interleukin-33 (IL-33), a cytokine produced by cardiac fibroblasts, causes two opposing effects: (1) the binding of IL-33 and ST2L results in cardioprotective effects against hypertrophic remodeling and myocardial fibrosis by antagonizing angiotensin-II signaling and promoting anti-apoptotic factors, respectively; (2) sST2 bound to IL-33 acts as a decoy receptor, and inhibits the protective effects of IL-33 and ST2L in cardiac myocytes [51,52].